Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter study to determine the efficacy and safety of first-line
lenalidomide plus rituximab therapy in patients with mantle cell lymphoma who have received
no prior systemic therapy.